Advertisement

Vitiligo pp 481-483 | Cite as

Editor’s Synthesis and Perspectives

  • Alain TaïebEmail author
  • Mauro Picardo
Chapter

Abstract

EBM guidelines have many limitations in a field like vitiligo but can help to fight charlatanism and harmful interventions. Inflammation/autoimmunity are the major targets to stop disease progression. Combination therapies using systemic/topical antiinflammatory-immunosuppressant drugs with UVB therapy are the current mainstay approach for vitiligo. More targeted immunosuppressants such as Jak inhibitors are currently in clinical development Novel approaches should promote melanocyte survival and stability within the basal membrane zone of the epidermis.

Regenerative medicine is the next important development because of the exhaustion of spontaneous regeneration especially in acral locations.

References

  1. 1.
    Whitton M, Pinart M, Batchelor JM, Leonardi-Bee J, Gonzalez U, Jiyad Z, Eleftheriadou V, Ezzedine K. Evidence-based management of vitiligo: summary of a Cochrane systematic review. Br J Dermatol. 2016;174(5):962–9.  https://doi.org/10.1111/bjd.14356. Epub 2016 Mar 25. Review. PubMed PMID: 26686510.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M, Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Europe´enne des Me´decins Spe´cialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19.  https://doi.org/10.1111/j.1365-2133.2012.11197.x. Epub 2012 Nov 2. PubMed PMID: 22860621.
  3. 3.
    Boniface K, Seneschal J. Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. Exp Dermatol. 2019;  https://doi.org/10.1111/exd.13879. [Epub ahead of print] Review. PubMed PMID: 30636075.
  4. 4.
    Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151(1):42–50.  https://doi.org/10.1001/jamadermatol.2014.1875. PubMed PMID: 25230094.CrossRefPubMedGoogle Scholar
  5. 5.
    Bondanza S, Maurelli R, Paterna P, et al. Keratinocyte cultures from involved skin in vitiligo patients show an impaired in vitro behaviour. Pigment Cell Res. 2007;20:288–300.CrossRefGoogle Scholar
  6. 6.
    Lan CC, Wu CS, Chiou MH, et al. Low-energy helium-neon laser induces locomotion of the immature melanoblasts and promotes melanogenesis of the more differentiated melanoblasts: recapitulation of vitiligo repigmentation in vitro. J Invest Dermatol. 2006;126:2119–26.CrossRefGoogle Scholar
  7. 7.
    Kapoor R, Phiske MM, Jerajani HR. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol. 2009;160:861–3.CrossRefGoogle Scholar
  8. 8.
    Takahashi K, Tanabe K, Ohnuki M. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hôpital Saint-André Service de DermatologieBordeauxFrance
  2. 2.Cutaneous Physiopathology and CIRMSan Gallicano Dermatological Institute, IRCCSRomeItaly

Personalised recommendations